Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...

PITTSBURGH, Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of Viatris' equity stake ...

Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m. Viatris will sell all of its convertible preferred equity in Biocon Biologics. The ...

(RTTNews) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the agreements, Biocon ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of a number of divestitures ...

Kiran Mazumdar-Shaw of Biocon & Biocon Biologics discusses the company's acquisition of Viatris' biosimilars business and says Indian investors are "very wary" of overseas acquisitions and there was a ...

Biocon’s recent biosimilar track record at the FDA isn’t looking so hot. Following an insulin copycat slap-down last month, Biocon on Sunday revealed (PDF) a complete response letter from the FDA on a ...

Viatris (NASDAQ: VTRS) makes both generic and branded drugs and its stock looks like a potential steal of a deal at the moment. It trades at less than 6 times its earnings, and it pays a dividend that ...

The transaction accelerates the expiration of biosimilars non-compete restrictions, the company said. The shares are subject to a six-month lock up period. Transaction value will be subject to related ...